Frazier Healthcare Partners, a Seattle, Wash., and Menlo Park, Calif.-based healthcare-focused investment firm, has promoted three investments professionals on the Life Sciences team.
They are Dan Estes, Ph.D. to Partner, Remy Durand, Ph.D. to Vice President, and Jamie Brush, M.D. to Senior Associate.
Dan Estes joined the Frazier Life Sciences team in 2011 and serves on the boards of Semnur Pharmaceuticals and Outpost Medicine. He has also played key roles in Frazier’s investments in Acerta Pharma (acquired by AstraZeneca), Tobira Therapeutics (acquired by Allergan), Cidara Therapeutics (NASDAQ: CDTX), Precision Dermatology (acquired by Valeant), Millendo Therapeutics and Entasis Therapeutics, among others.
Remy Durand joined Frazier in 2015 and has been involved with all life sciences deals since that time. He is an observer on the boards of Alpine Immune Sciences, Aptinyx Inc., Iterum Therapeutics and Zavante Therapeutics.
Jamie Brush joined the Frazier Life Sciences team in 2016. Prior to joining Frazier, he was a management consultant at Boston Consulting Group. He received his M.D. from the University of Southern California.
Founded in 1991, Frazier Healthcare Partners is a U.S.-based healthcare-focused investment firm providing private growth capital to healthcare companies. The firm has more than $2.9 billion in committed capital under management and has made investments in more than 170 companies ranging from early-stage venture investments to growth buyouts of profitable lower middle market companies.
The firm has offices in and invests broadly across the United States, Canada and Europe.
FinSMEs
05/01/2017